Related Experiment Videos
Emerging antiangiogenic agents in lung cancer
1CIG Media Group, LP, Dallas, TX, USA.
Clinical Lung Cancer
|April 28, 2006
Summary
Novel antiangiogenic agents targeting vascular endothelial growth factor (VEGF) are being developed to treat cancers like non-small-cell lung cancer (NSCLC). These agents, including receptor tyrosine kinase (TK) inhibitors and VEGF Trap, show clinical feasibility in ongoing trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The success of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has driven research into new antiangiogenic therapies.
- Novel agents aim to inhibit VEGF signaling through various mechanisms, including receptor tyrosine kinase (TK) inhibition and direct VEGF binding.
Purpose of the Study:
- To review novel antiangiogenic agents developed following the success of bevacizumab.
- To discuss agents targeting VEGF receptor TK activity and VEGF itself, including their mechanisms and clinical development status.
Main Methods:
- Review of small-molecule receptor tyrosine kinase (TK) inhibitors (ZD6474, sorafenib, sunitinib malate, AG-013736) that inhibit VEGF receptor TK activity.
- Description of VEGF Trap, a fusion molecule targeting VEGF with high affinity.
- Summary of clinical trial data (Phase I/II) indicating feasibility.
Main Results:
- Receptor TK inhibitors exhibit broad activity, inhibiting multiple receptors due to structural similarities.
- VEGF Trap demonstrates specificity for the VEGF molecule.
- Phase I/II trials suggest these novel antiangiogenic agents are clinically feasible.
Conclusions:
- Ongoing Phase II/III trials are evaluating the efficacy of these novel antiangiogenic agents.
- The development of diverse antiangiogenic strategies, including TK inhibitors and VEGF Trap, offers promising therapeutic avenues for cancers such as non-small-cell lung cancer (NSCLC).